Statins, competitive inhibitors of HMGCR, and proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) inhibitors are the mainstays of preventive therapy in cancer patients as in the general population (144, 145). This evidence concerns the gene HMGCR and cancer.